Francesco Forconi, MD, DM, PhD, FRCPath, University of Southampton, Southampton, UK, outlines the treatment options available at present for patients with chronic lymphocytic leukemia (CLL) and discusses the current development of novel BTK degraders. This interview took place at the 20th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved